John Ebos (PhD) is an Assistant Professor of Oncology in the Departments of Cancer Genetics and Medicine at Roswell Park Cancer Institute (RPCI), and is a member of the graduate faculty in the Department of Pharmacology and Therapeutics at the State University of New York at Buffalo.

Dr. Ebos completed his undergraduate training at McGill University and earned his PhD in the Department of Medical Biophysics at the University of Toronto under the mentorship of Dr. Robert S. Kerbel where he studied novel circulating molecules as potential surrogate markers of cancer progression and antiangiogenic drug efficacy.

Dr. Ebos doctoral studies led to the discovery of a soluble form of a key receptor for the vascular endothelial growth factor (VEGF) pathway, the ligand/receptor pairing that is the central target for all antiangiogenic therapies now FDA approved in several different cancer types. This soluble receptor (termed ‘sVEGFR-2’), along with several other circulating cytokines, were then studied as indicators of off-target ‘host’ effects following therapy and investigated for their potential to facilitate disease progression.

Dr. Ebos’ laboratory currently focuses on the molecular mechanisms that drive intrinsic and acquired drug resistance to stromal inhibitors in the treatment of spontaneous metastatic disease in mouse surgical models. This includes late-stage systemic metastasis as well as early-stage perioperative settings, such as with adjuvant and neoadjuvant treatment settings. The long-term goal of these efforts is to conduct preclinical models in conjunction with ongoing clinical trials so that benefits can be more readily predicted and rational designs for subsequent/alternative therapies can be developed.